RYE, N.Y., July 17, 2012 /PRNewswire/ -- Curemark today announced the appointment of Matthew F. Heil, PhD, to the position of Chief Scientific Officer.  Currently, Dr. Heil is serving as Curemark's Senior Vice President for Research and Product Development.  

Additionally, Curemark announced the appointment of James Szigethy, R. Ph. to the position of Vice President of Research and Product Development from Director of Research and Product Development.

Dr. Joan Fallon, Curemark Founder and CEO, announced the promotions and stated, "Dr. Heil's contributions and strategic insight into our product pipeline as well as our Phase III trial for CM-AT in autism have been invaluable.  As we maximize the value of our products and platform, Dr. Heil is the perfect person to lead the charge.  He is an accomplished scientist and wonderful collaborator."

Dr. Heil commented, "Working on the development of Curemark's autism product has been the highlight of my professional career.  Leading Curemark's scientific team is a very exciting opportunity and I'm thrilled that I will be able to work closely with James Szigethy in his new capacity as we move to optimize our product pipeline."

Dr. Heil has more than two decades of experience in the pharmaceutical and biotechnology industries, and has served on multiple corporate boards.  His successful areas of work include product development, regulatory affairs, strategic partnering and epidemiologic analysis. Dr. Heil received his PhD from Syracuse University in Immunology and has been a faculty member of the New York College of Medicine, as well as co-director of its clinical immunology-testing laboratory.

James Szigethy is a graduate of Rutgers University College of Pharmacy and received his BA in Psychology from St. John's University in Queens, New York.


Curemark is a drug research and development company focused on the treatment